Rogerio C. Lilenbaum, MD

Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow Cancer Hospital

Physician Biography

Dr. Lilenbaum received his medical degree from the Federal University of Rio de Janeiro School of Medicine in Brazil and earned a masters degree in clinical epidemiology and clinical investigation from the Harvard School of Public Health. He completed his hematology/oncology fellowship at Washington University School of Medicine and a clinical and research fellowship at the University of California San Diego.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Thoracic Oncology Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Internal Medicine AB of Internal Medicine (1995)

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

  • Medical Oncology AB of Internal Medicine (1997)

Clinical Trials

Conditions Study Title
Lung TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
Lung A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE: Phase 1b/2 INvestigation of anti-Notch Antibody Therapy with Cisplatin and Etoposide in Small Cell Lung Carcinoma Safety and Efficacy)
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Lung Lung Cancer Mutation Consortium Protocol
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (S1206/NCI Study Number 8811)
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Lung, Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Lung A Phase Ib Study of the Safety and Pharmacology of MPDL3280A administered with Erlotinib or Alectinib in Patients with Advanced Non-Small Cell Lung Cancer
Lung A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Lung A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)
Lung A Phase III, Randomized, Open-label, Crossover, Multi-center, Safety and Efficacy Study to Evaluate NAB-PACLITAXEL (ABRAXANE®) as Maintenance Treatment After Induction with NAB-PACLITAXEL plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Lung A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Lung S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Unknown Sites Tumor Molecular Profiling
Lung A Phase 2, Multicenter, Single-arm Study of Oral AP26113 in Patients with ALK-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated with Crizotinib
Melanoma, skin A PHASE 1b STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Lung, Melanoma, skin A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients with Metastatic Melanoma or NSCLC
Lung A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung S1403: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)

Edit this profile

Contact Info

Rogerio C. Lilenbaum, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 4

New Haven, CT 06511
Mailing Address
20 York Street
New Haven, CT 06520-8021